Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
February 13, 2024 at 04:21 pm EST
Share
Rezolute, Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported net loss was USD 13.91 million compared to USD 13.56 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.26 a year ago.
For the six months, net loss was USD 28.43 million compared to USD 23.39 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.55 compared to USD 0.46 a year ago.
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
REZOLUTE, INC. 
